Niagen Biosciences, Inc. Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $34 million, up 33% year-over-year.

Net Income: $4.6 million ($0.06 per share), compared to $1.9 million ($0.02 per share) in Q3 2024.

Cash Position: $64.3 million with no debt.

E-commerce Sales: $19 million, a 29% increase year-over-year.

Distribution Revenue: Grew 109% year-over-year to $7 million.

Niagen Ingredient Revenue: Steady at $6.9 million, a 4% increase year-over-year.

Gross Margin: Improved to 64.5%, up from 63.5% a year ago.

2Strategic Updates and Business Highlights

New Partnership: Onboarded a strategic partner with access to over 8,000 healthcare practitioners, enhancing the distribution of Tru Niagen.

Niagen Plus Launch: At-home injection kits launched, currently available only via prescription, with plans for telehealth platform integration.

Clinical Studies: Ongoing studies on NR supplementation for long COVID and other conditions, with results expected in early 2026.

Market Positioning: Emphasis on Niagen as the most effective NAD booster, supported by over 40 peer-reviewed studies.

3Forward Guidance and Outlook

Revenue Growth Guidance: Revised upward from 22%-27% to 25%-30% year-over-year for 2025.

R&D Expenses: Expected to decline as a percentage of sales but increase in absolute terms.

General and Administrative Expenses: Anticipated to rise to $8-$9 million year-over-year, primarily due to increased share-based compensation.

4Bad News, Challenges, or Points of Concern

FDA Decision on NMN: The reversal of NMN's marketing status may lead to increased competition, although no immediate impact on sales was noted.

Market Competition: Presence of unregulated NMN products and potential patent infringements pose risks.

Pricing Pressures: Ongoing requests from ingredient partners for price reductions, regardless of market changes.

Market Penetration: The injection and IV markets are still developing, with pricing issues limiting growth potential.

5Notable Q&A Insights

Partnership Uptake: Early feedback on the new partnership for IV products is not yet available as the rollout has just begun.

Consumer Behavior Post-FDA Announcement: No significant changes in purchasing behavior observed following the FDA's NMN decision.

Telehealth Integration: Plans to develop a telehealth platform for at-home injections are underway, expected to launch in mid-2026.

Pharmaceutical Ventures: Discussion of establishing a stand-alone entity for pharmaceutical applications, particularly for Parkinson's disease, is in consideration, pending study results. This summary encapsulates the key financial performance, strategic initiatives, forward-looking guidance, and challenges faced by Niagen Biosciences during Q3 2025, along with insights from the Q&A session.